Pfizer Limited has announced the launch of its next-generation 20-valent Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed) I.P., 20 – Valent (PCV20) for adults in the Indian market. This innovative vaccine marks a significant advancement in the prevention of pneumococcal disease, offering broader protection than any previously available conjugate vaccine in India.

Expanded Protection Against Pneumococcal Disease

The newly introduced PCV20 vaccine is designed to provide protection against 20 serotypes of Streptococcus pneumoniae, the bacterium responsible for pneumococcal disease. This expanded coverage aims to address a wider range of pneumococcal infections, including both invasive and non-invasive forms of the disease.

Key Features of PCV20

• Single-Dose Efficacy: PCV20 is administered as a single shot, potentially eliminating the need for a second dose.
• Broad Serotype Coverage: The vaccine targets 20 clinically relevant serotypes, offering more comprehensive protection than previous vaccines.
• Adult-Focused: Approved for use in adults 18 years of age and older, addressing the increasing need for adult immunization in India.

Target Population and Health Impact

Meenakshi Nevatia, Managing Director of Pfizer Ltd., India, emphasized the importance of this launch, stating, "We believe this vaccine, with its broad coverage of 20 pneumococcal disease serotypes, will address the increasing need for adult immunization in our country."

The vaccine is particularly significant for:

• Adults over 50 years of age
• Individuals with comorbidities such as asthma, COPD, chronic kidney disease, and diabetes

These groups face a higher risk of developing pneumococcal infections, which can lead to severe complications, hospitalization, and mortality.

Public Health Significance

Pneumococcal conjugate vaccines are recognized as one of the most effective public health tools for reducing the burden of pneumococcal disease. The introduction of PCV20 in India aligns with Pfizer's commitment to preventive health and builds on its 25-year leadership in pneumococcal vaccine innovation.

Availability and Launch Details

According to the official announcement:

• Launch Date: August 11, 2025
• Market: Available for the domestic Indian market
• Product Category: Pneumococcal Polysaccharide Conjugate Vaccine

This launch represents a significant step forward in adult immunization in India, offering a new tool in the fight against pneumococcal disease and its potentially severe consequences.

Pfizer's introduction of the 20-valent pneumococcal conjugate vaccine underscores the company's ongoing efforts to address critical health challenges and improve public health outcomes in India and globally.

Pfizer Ltd , a prominent pharmaceutical company, saw its shares surge by over 12% following the announcement of its Q4 results and a substantial dividend payout. The company's impressive performance and generous shareholder returns have caught the attention of investors, leading to a significant uptick in its stock price.

Strong Q4 Performance

Pfizer's Q4 results showcased remarkable growth across key financial metrics:

• Net Profit: The company reported an impressive 85% jump in net profit to ₹330.94 crore, demonstrating strong bottom-line growth.
• Revenue Growth: Pfizer's revenue increased by 8.3% to ₹591.91 crore, indicating robust sales performance across its product portfolio.
• EBITDA Boost: Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) saw a substantial 20% rise to ₹227.50 crore, reflecting improved operational efficiency and profitability.
• EBITDA Margin: The EBITDA margin expanded to 38.4%, showcasing the company's ability to manage costs effectively while growing its revenue.

Financial Highlights

Dividend Announcement

In a move that has delighted shareholders, Pfizer Ltd declared a final dividend of ₹35 per share. This generous payout further underscores the company's commitment to delivering value to its investors.

Stock Market Response

The combination of strong financial results and the attractive dividend payout has created a highly positive sentiment among investors. This was reflected in the significant jump in Pfizer Ltd's share price, which surged over 12% to ₹4,990.

Looking Ahead

Pfizer Ltd's impressive Q4 results and the dividend announcement have positioned the company favorably in the eyes of investors. The significant share price increase demonstrates market confidence in Pfizer's financial health and future prospects. As the pharmaceutical sector continues to play a crucial role in global healthcare, Pfizer Ltd's strong performance suggests it remains well-positioned to capitalize on opportunities in the Indian market and beyond.